Crohn's disease
![Jyseleca Withdrawn in Europe: Galapagos Cuts Sales Forecast](https://pharmtales.com/wp-content/uploads/2023/08/Galapagos-Drops-Jyseleca-in-Europe-Lowers-Sales-Outlook.jpg)
Galapagos Drops Jyseleca in Europe, Lowers Sales Outlook
SG Tylor
Galapagos has suffered a significant setback as it decided not to submit a Marketing Authorization Application (MAA) for its drug ...
![Roche's Potential $7billion Acquisition_ Exploring the Purchase of Roivant's Promising Drug](https://pharmtales.com/wp-content/uploads/2023/07/Roches-Potential-7billion-Acquisition_-Exploring-the-Purchase-of-Roivants-Promising-Drug.jpg)
Roche’s Potential $7billion Acquisition: Exploring the Purchase of Roivant’s Promising Drug
SG Tylor
According to media reports, Roche is said to be in the final stages of negotiations with Roivant for a potential ...